Inhibition of amphetamine- and apomorphine-induced behavioural effects by neuropeptide Y Y1 receptor antagonist BIBO 3304

Neuropharmacology

Volumn 39, Issue 7, 2000, Pages 1292-1302

  Kask, A ^a   Harro, J ^a  

^a UNIVERSITY OF TARTU   (Estonia)

Author keywords

Aggression; Amphetamine; Apomorphine; BIBO 3304; BIBP 3226; Dopamine; Hyperactivity; Locomotor activity; Neuropeptide Y; NPY Y1 receptor antagonist

Indexed keywords

AMPHETAMINE; APOMORPHINE; N2 DIPHENYLACETYL N (4 UREIDOMETHYLBENZYL)ARGININAMIDE; NALPHA (DIPHENYLACETYL) N (4 HYDROXYBENZYL) DEXTRO ARGININAMIDE; NEUROPEPTIDE Y RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

AGGRESSIVENESS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DRUG EFFECT; ENANTIOMER; HYPERACTIVITY; LOCOMOTION; MALE; NONHUMAN; OPEN FIELD BEHAVIOR; PRIORITY JOURNAL; RAT; REARING; STRESS;

AGGRESSION; AMPHETAMINE; ANIMALS; APOMORPHINE; ARGININE; BEHAVIOR, ANIMAL; CENTRAL NERVOUS SYSTEM STIMULANTS; DOPAMINE AGONISTS; INJECTIONS, INTRAVENTRICULAR; INJECTIONS, SUBCUTANEOUS; MALE; MICROINJECTIONS; MOTOR ACTIVITY; RATS; RATS, WISTAR; RECEPTORS, NEUROPEPTIDE Y;

EID: 0034117402     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(99)00199-9     Document Type: Article

References (36)

1. Allikmets L.H., Vasar E. Sensitisation of male rats to aggressive behavior. Zhurnal Vysshei Nervnoi Deiatelnosti. 32:1982;130-135.
2. 1-like receptor. Journal of Pharmacology and Experimental Therapeutics. 284:1998;553-560.
3. 3H]dopamine release from rat striatum by neuropeptide Y and sigma receptor ligands. Brain Research. 760:1997;210-217.
4. Badiani A., Oates M.M., Day H.E., Watson S.J., Akil H., Robinson T.E. Amphetamine-induced behaviour, dopamine release, and c-fos mRNA expression: modulation by environmental novelty. Journal of Neuroscience. 18:1998;10579-10593.
5. Beninger R.J. The role of dopamine in locomotor activity and learning. Brain Research. 287:1983;173-196.
6. Broadhurst P.L. The Maudsley reactive and nonreactive strains of rats: a survey. Behavioural Genetics. 5:1975;299-319.
7. Broqua P., Wettstein J.G., Rocher M.N., Gauthier-Martin B., Junien J.L. Behavioral effects of neuropeptide Y receptor agonists in the elevated plus-maze and fear-potentiated startle procedures. Behavioural Pharmacology. 6:1995;215-222.
8. Frederiksen S.O., Ekman R., Gottfries C.G., Widerlöv E., Jonsson S. Reduced concentrations of galanin, arginine vasopressin, neuropeptide Y and peptide YY in the temporal cortex but not in the hypothalamus of brains from schizophrenics. Acta Psychiatrica Scandinavica. 83:1991;273-277.
9. Hasselager E., Rolinski Z., Randrup A. Specific antagonism by dopamine inhibitors of items of amphetamine induced aggressive behaviour. Psychopharmacologia. 24:1972;485-495.
10. Heilig M., Söderpalm B., Engel J.A., Widerlöv E. Centrally administered neuropeptide Y (NPY) produces anxiolytic-like effects in animal anxiety models. Psychopharmacology. 98:1989;524-529.
11. Heilig M., Wahlestedt C., Widerlöv E. Neuropeptide Y (NPY)-induced suppression of activity in the rat: evidence for NPY receptor heterogeneity and for interaction with α-adrenoceptors. European Journal of Pharmacology. 157:1988;205-213.
12. Josselyn S.A., Beninger R.J. Neuropeptide Y: intraaccumbens injections produce place preference that is blocked by cis-flupenthixol. Pharmacology and Biochemical Behavior. 46:1993;543-552.
13. Junien J.L., Gué M., Bueno L. Neuropeptide Y and sigma ligand (JO 1784) act through a Gi protein to block the psychological stress and corticotropin-releasing factor-induced colonic motor activation in rats. Neuropharmacology. 30:1991;1119-1124.
14. 1 receptor antagonist BIBP3226: antagonism with diazepam. European Journal of Pharmacology. 317:1996;R3-R4.
15. 9-41 prevents anxiogenic-like effect of NPY Y1 receptor antagonist BIBP3226 in rats. NeuroReport. 8:1997;3645-3647.
16. 1 receptor antagonist BIBP3226 administered into the dorsal periaqueductal gray matter in rats. Regulatory Peptides. 75-76:1998;255-262.
17. Lang A., Harro J., Soosaar A., Kõks S., Volke V., Oreland L., Bourin M., Vasar E., Bradwejn J., Männistö P.T. Role of N-methyl-D-aspartic acid and cholecystokinin receptors in apomorphine-induced aggressive behaviour in rats. Naunyn-Schmiedeberg's Archives of Pharmacology. 351:1995;363-370.
18. Mattingly B.A., Koch C., Osborne F.H., Gotsick J.E. Stimulus and response factors affecting the development of behavioural sensitization to apomorphine. Psychopharmacology. 130:1997;109-116.
19. 2 receptor binding charateristics. Medical Science Research. 26:1998;499-501.
20. 3H]citalopram binding after antidepressant treatment in rats. Pharmacology Biochemical Behavior. 59:1998;747-752.
21. Michel M.C., Beck-Sickinger A., Cox H., Doods H.N., Herzog H., Larhammar D., Quirion R., Schwartz T., Westfall T. XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors. Pharmacological Reviews. 50:1998;143-150.
22. Moore E., Merali Z., Beninger R.J. Neuropeptide Y: intrastriatal injections produce contralateral circling that is blocked by a dopamine antagonist in rats. Pharmacology and Biochemical Behavior. 48:1994;681-688.
23. Obuchowics E. Long-term treatment with chlorpromazine and haloperidol but not with sulpiride and clozapine markedly elevates neuropeptide Y-like immunoreactivity in the rat hypothalamus. Neuropeptides. 30:1996;471-478.
24. Obuchowics E., Turchan J. Influence of typical and atypical antipsychotics on neuropeptide Y-like immunoreactivity and NPY mRNA expression in rat striatum. Neuropeptides. 32:1998;473-480.
25. Peters J., Van Kammen D.P., Gelernter J., Yao J., Shaw D. Neuropeptide Y-like immunoreactivity in schizophrenia: relationships with clinical measures. Schizophrenia Research. 3:1990;287-294.
26. Rots N.Y., Cools A.R., Berod A., Voorn B., Rostene W., de Kloet E.R. Rats bred for enhanced apomorphine susceptibility have elevated tyrosine hydroxylase mRNA and dopamine D2-receptor binding sites in nigrostriatal and tuberoinfundibular dopamine systems. Brain Research. 710:1996;189-196.
27. Rudolf K., Eberlein W., Engel W., Wieland H.A., Willim K.D., Entzeroth M., Wienen W., Beck-Sickinger A.G., Doods H. The first potent and selective non-peptide neuropeptide Y Y1 receptor antagonist BIBP 3226. European Journal of Pharmacology. 271:1994;R11-R13.
28. 1 receptors mediate the anxiolytic-like actions of neuropeptide Y in the social interaction test. European Journal of Pharmacology. 368:1999;143-147.
29. Sakai K., Maeda K., Chihara K., Kaneda H. Increases in cortical neuropeptide Y and somatostatin concentrations following haloperidol-depot treatment in rats. Neuropeptides. 29:1995;157-161.
30. Strömbom U. Antagonism by haloperidol of locomotor depression induced by small doses of apomorphine. Journal of Neural Transmission. 40:1977;191-194.
31. Sutanto W., de Kloet E.R. The use of various animal models in the study of stress and stress-related phenomena. Laboratory Animals. 28:1994;293-306.
32. Tassin J.-P., Tarracq L., Blanc G., Trovero F. Integrating monoamine systems. Briley M., Montgomery S. Antidepressant Therapy at the Dawn of the Third Millenium. 1998;1-18 Martin Dunitz.
33. Tatsuoka Y., Riskind P.N., Beal M.F., Martin J.B. The effect of amphetamine on the in vivo release of dopamine, somatostatin and neuropeptide Y from rat caudate nucleus. Brain Research. 441:1987;200-203.
34. Tessel R.E., DiMaggio D.A., O'Donohue T.L. Amphetamine-induced changes in immunoreactive NPY in rat brain, pineal gland and plasma. Peptides. 6:1985;1219-1224.
35. Wettstein J.G., Earley B., Junien J.L. Central nervous system pharmacology of neuropeptide Y. Pharmacology and Therapeutics. 65:1995;397-414.
36. Wieland H.A., Engel W., Eberlein W., Rudolf K., Doods H.N. Subtype selectivity of the novel nonpeptide neuropeptide Y Y1 receptor antagonist BIBO 3304 and its effect on feeding in rodents. British Journal of Pharmacology. 125:1998;549-555.